VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo
about
The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspiratorCorticotropin-releasing factor receptor 2 is a tonic suppressor of vascularizationLITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growthSignal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors.New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders.Angiogenesis in epithelian ovarian cancer.Two functionally distinct isoforms of TL1A (TNFSF15) generated by differential ectodomain sheddingTenomodulin inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathyVascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors.c-Myc is essential to prevent endothelial pro-inflammatory senescent phenotype.Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsiaIntraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells.TNFSF15 Modulates Neovascularization and InflammationEffects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis.Molecule action mechanisms of NM-3 on human gastric cancer SGC-7901 cells in vivo or in vitroTL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune diseasePreparation and characterization of a novel chimeric protein VEGI-CTT in Escherichia coli.TNFSF15 Inhibits Blood Retinal Barrier Breakdown Induced by DiabetesInhibition of endothelial progenitor cell differentiation by VEGI.Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer modelsChanges in TL1A levels and associated cytokines during pathogenesis of diabetic retinopathy.Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic functionInhibitory effect of tenomodulin versus ranibizumab on in vitro angiogenesis.Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.Inhibition of corneal neovascularization by vascular endothelia growth inhibitor geneCharacterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter.Inhibition of corneal neovascularization by vascular endothelia growth inhibitor geneCounterbalance: modulation of VEGF/VEGFR activities by TNFSF15
P2860
Q26799347-40493E7B-A3E8-4E22-B00F-D2208967AD63Q28511231-8BB8BF8C-59A5-41E2-9F20-D8EFB257CA64Q30179387-6E91F094-879D-486B-B422-8377D47E6908Q33782305-BDEB1CF1-5246-40CF-B4B2-B534E755D39DQ33801264-98BB54E8-0A1C-47A6-9338-7EACF99F7F11Q33919078-44A4E4C2-352C-4CD7-8F35-0D298254D89DQ34195262-52971CEB-223E-4A53-A6B4-6BBCDDDB4331Q34314903-8DC3EC38-DEC5-4500-815F-F730ED13711FQ34587733-69BCB7F9-D455-4F9A-81DF-A3188F83E747Q34988841-F7C18D08-3C97-4477-8392-6347040C2D42Q35208938-A6FD136F-AE8A-446B-9E2A-2EA554996102Q35876847-720D7E7E-1DDA-442C-B5A9-833525FBEE0EQ36284920-D8FEC827-55C0-4DD6-8FF3-57F2C12940E9Q36308083-0A1FB03A-A81F-4D65-898F-6139875E2C0CQ36308777-B8EA80E9-2BA6-4EA6-A36C-3AC12AED0B73Q36639973-746A8B7B-3F11-488D-A12D-3F35CF84F2D6Q36844365-88995BBB-74BB-4855-A0A1-726776891BD0Q36939054-8CB944B2-6C9B-4A73-A8B2-9AEB2BBB66CDQ37202006-7C131A93-4A39-4E16-8B8A-F94A718CBD89Q37688606-31AB275D-CD03-4BA8-86DE-47ABF4B2EAF8Q37720009-EB46C9C8-79A0-4507-BE86-0A2F2AD69A34Q38043456-160B6385-5FB5-4CBB-9048-D61CD3EBB6B0Q39912239-CA939B3E-11D9-42D1-94A7-803901629549Q40061856-4DA8A2BA-8F63-42A9-A6C6-81D2331CC40AQ40394988-4E289AF4-7D47-4864-A4D4-62CEDC00C8EBQ42013131-42ADCF02-F130-41D0-90EA-2366DE6BD7DFQ42260610-092E1DDA-73EC-4283-A5B2-64F4E2548F69Q57219256-AC46CF68-CB0F-453C-9C69-849B85D00C23Q58791672-513D13C6-6DB7-4806-ADDC-74E931E3B0CA
P2860
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@ast
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@en
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@en-gb
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@nl
type
label
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@ast
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@en
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@en-gb
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@nl
prefLabel
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@ast
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@en
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@en-gb
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@nl
P2093
P3181
P356
P1433
P1476
VEGI, a novel cytokine of the ...... th of colon carcinomas in vivo
@en
P2093
B B Aggarwal
K C Carter
P304
P3181
P356
10.1096/FASEBJ.13.1.181
P407
P577
1999-01-01T00:00:00Z